HUE029247T2 - Benzimidazole Respiratory Syncytial Virus Inhibitors - Google Patents
Benzimidazole Respiratory Syncytial Virus Inhibitors Download PDFInfo
- Publication number
- HUE029247T2 HUE029247T2 HUE11802054A HUE11802054A HUE029247T2 HU E029247 T2 HUE029247 T2 HU E029247T2 HU E11802054 A HUE11802054 A HU E11802054A HU E11802054 A HUE11802054 A HU E11802054A HU E029247 T2 HUE029247 T2 HU E029247T2
- Authority
- HU
- Hungary
- Prior art keywords
- ágy ágy
- compound
- formula
- previous
- chemical
- Prior art date
Links
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- 241000725643 Respiratory syncytial virus Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 206010016531 fetishism Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 150000001412 amines Chemical group 0.000 description 4
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 3
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 3
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 150000004696 coordination complex Chemical group 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10195467 | 2010-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE029247T2 true HUE029247T2 (en) | 2017-02-28 |
Family
ID=43875271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE11802054A HUE029247T2 (en) | 2010-12-16 | 2011-12-16 | Benzimidazole Respiratory Syncytial Virus Inhibitors |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8865705B2 (enExample) |
| EP (1) | EP2651903B1 (enExample) |
| JP (1) | JP6005656B2 (enExample) |
| KR (1) | KR101876240B1 (enExample) |
| CN (2) | CN107417683A (enExample) |
| AR (1) | AR085203A1 (enExample) |
| AU (1) | AU2011343255B2 (enExample) |
| BR (1) | BR112013012137A2 (enExample) |
| CA (1) | CA2821999C (enExample) |
| CL (1) | CL2013001713A1 (enExample) |
| CY (1) | CY1117751T1 (enExample) |
| DK (1) | DK2651903T3 (enExample) |
| EA (1) | EA022972B1 (enExample) |
| ES (1) | ES2576180T3 (enExample) |
| HK (1) | HK1247616A1 (enExample) |
| HR (1) | HRP20160650T1 (enExample) |
| HU (1) | HUE029247T2 (enExample) |
| IL (1) | IL225640A (enExample) |
| MX (1) | MX340030B (enExample) |
| MY (1) | MY156641A (enExample) |
| NZ (1) | NZ609450A (enExample) |
| PH (1) | PH12013500796A1 (enExample) |
| PL (1) | PL2651903T3 (enExample) |
| PT (1) | PT2651903E (enExample) |
| SG (1) | SG190766A1 (enExample) |
| SI (1) | SI2651903T1 (enExample) |
| TW (1) | TWI530495B (enExample) |
| UA (1) | UA112298C2 (enExample) |
| WO (1) | WO2012080446A1 (enExample) |
| ZA (1) | ZA201304424B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| TWI530495B (zh) | 2010-12-16 | 2016-04-21 | 健生科學愛爾蘭無限公司 | 苯并咪唑呼吸道融合病毒抑制劑 |
| TWI527814B (zh) * | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
| TWI501967B (zh) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
| TWI541241B (zh) | 2010-12-16 | 2016-07-11 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 |
| CA2873920C (en) | 2012-06-15 | 2021-07-20 | Janssen R&D Ireland | 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents |
| WO2013186334A1 (en) * | 2012-06-15 | 2013-12-19 | Janssen R&D Ireland | 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents |
| BR112015000392A2 (pt) * | 2012-07-10 | 2017-06-27 | Hoffmann La Roche | novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório |
| AU2013334001B2 (en) | 2012-10-16 | 2017-07-20 | Janssen Sciences Ireland Uc | RSV antiviral compounds |
| JP6383735B2 (ja) * | 2013-01-28 | 2018-08-29 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Ｒｓウイルスの抗ウイルス剤としてのキノキサリノンおよびジヒドロキノキサリノン |
| JP2016518421A (ja) | 2013-05-14 | 2016-06-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール |
| HK1222855A1 (zh) | 2013-08-15 | 2017-07-14 | F. Hoffmann-La Roche Ag | 新的用於治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚 |
| CA2921294C (en) | 2013-08-21 | 2023-05-16 | Alios Biopharma, Inc. | Antiviral compounds |
| WO2015065336A1 (en) * | 2013-10-29 | 2015-05-07 | Medivir Ab | Respiratory syncytial virus inhibitors |
| TWI671299B (zh) | 2014-04-14 | 2019-09-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 作為ｒｓｖ抗病毒化合物之螺脲化合物 |
| MA40404A (fr) * | 2014-08-05 | 2017-06-14 | Alios Biopharma Inc | Polythérapie pour traiter un paramyxovirus |
| MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
| MY197231A (en) | 2015-07-22 | 2023-06-06 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| CN108699077B (zh) | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
| WO2018152413A1 (en) | 2017-02-16 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| CN111386118B (zh) | 2017-09-29 | 2023-05-09 | 英安塔制药有限公司 | 作为rsv抑制剂的组合药物剂 |
| MX394621B (es) | 2017-11-13 | 2025-03-24 | Enanta Pharm Inc | Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona |
| WO2020190935A1 (en) | 2019-03-18 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as rsv inhibitors |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| PH12022550783A1 (en) | 2019-10-04 | 2023-07-31 | Enanta Pharm Inc | Antiviral heterocyclic compounds |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| JP2023528969A (ja) | 2020-06-11 | 2023-07-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | ３－（｛５－クロロ－１－［３－（メチルスルホニル）プロピル］－１Ｈ－インドール－２ イル｝メチル）－１－（２，２，２－トリフルオロエチル）－１，３－ジヒドロ－２Ｈ－イミダゾ［４，５－ｃ］ピリジン－２－オンのヘミ（Ｌ）－酒石酸塩形態及びそれを含む医薬組成物 |
| WO2022010882A1 (en) | 2020-07-07 | 2022-01-13 | Enanta Pharmaceuticals, Inc, | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors |
| WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| US12612412B2 (en) | 2021-02-26 | 2026-04-28 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| MX2023009961A (es) | 2021-02-26 | 2023-09-05 | Enanta Pharm Inc | Compuestos heterociclicos antivirales. |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| WO2024174953A1 (zh) * | 2023-02-21 | 2024-08-29 | 苏州隆博泰药业有限公司 | 苯并咪唑类衍生物及其医药用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0960102A1 (en) | 1996-07-08 | 1999-12-01 | Du Pont Pharmaceuticals Company | AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN |
| WO2000020400A1 (en) | 1998-10-05 | 2000-04-13 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions for treating hepatitis c infections |
| MXPA02000120A (es) | 1999-06-28 | 2002-07-02 | Janssen Pharmaceutica Nv | Inhibidores de la replicacion del virus sincitial respiratorio. |
| EP1418175A1 (en) | 1999-06-28 | 2004-05-12 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
| WO2001012600A1 (en) | 1999-08-12 | 2001-02-22 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| US6489338B2 (en) | 2000-06-13 | 2002-12-03 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrimidine antiviral agents |
| US6506738B1 (en) | 2000-09-27 | 2003-01-14 | Bristol-Myers Squibb Company | Benzimidazolone antiviral agents |
| US6919331B2 (en) * | 2001-12-10 | 2005-07-19 | Bristol-Myers Squibb Company | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents |
| US20040166137A1 (en) | 2002-11-08 | 2004-08-26 | Lackey John William | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| TWI501967B (zh) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
| TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| TWI541241B (zh) | 2010-12-16 | 2016-07-11 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 |
| TWI527814B (zh) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
| TWI530495B (zh) | 2010-12-16 | 2016-04-21 | 健生科學愛爾蘭無限公司 | 苯并咪唑呼吸道融合病毒抑制劑 |
-
2011
- 2011-12-15 TW TW100146390A patent/TWI530495B/zh not_active IP Right Cessation
- 2011-12-16 AU AU2011343255A patent/AU2011343255B2/en not_active Ceased
- 2011-12-16 WO PCT/EP2011/073008 patent/WO2012080446A1/en not_active Ceased
- 2011-12-16 KR KR1020137016944A patent/KR101876240B1/ko not_active Expired - Fee Related
- 2011-12-16 MY MYPI2013001281A patent/MY156641A/en unknown
- 2011-12-16 HU HUE11802054A patent/HUE029247T2/en unknown
- 2011-12-16 NZ NZ609450A patent/NZ609450A/en not_active IP Right Cessation
- 2011-12-16 AR ARP110104739A patent/AR085203A1/es active IP Right Grant
- 2011-12-16 EP EP11802054.4A patent/EP2651903B1/en active Active
- 2011-12-16 JP JP2013543799A patent/JP6005656B2/ja not_active Expired - Fee Related
- 2011-12-16 PL PL11802054.4T patent/PL2651903T3/pl unknown
- 2011-12-16 SG SG2013026711A patent/SG190766A1/en unknown
- 2011-12-16 PH PH1/2013/500796A patent/PH12013500796A1/en unknown
- 2011-12-16 CA CA2821999A patent/CA2821999C/en active Active
- 2011-12-16 DK DK11802054.4T patent/DK2651903T3/da active
- 2011-12-16 BR BR112013012137A patent/BR112013012137A2/pt not_active Application Discontinuation
- 2011-12-16 ES ES11802054.4T patent/ES2576180T3/es active Active
- 2011-12-16 CN CN201710103106.8A patent/CN107417683A/zh active Pending
- 2011-12-16 SI SI201130853A patent/SI2651903T1/sl unknown
- 2011-12-16 PT PT118020544T patent/PT2651903E/pt unknown
- 2011-12-16 EA EA201390888A patent/EA022972B1/ru not_active IP Right Cessation
- 2011-12-16 MX MX2013006886A patent/MX340030B/es active IP Right Grant
- 2011-12-16 HR HRP20160650TT patent/HRP20160650T1/hr unknown
- 2011-12-16 CN CN2011800602778A patent/CN103313974A/zh active Pending
- 2011-12-16 UA UAA201305027A patent/UA112298C2/uk unknown
- 2011-12-16 US US13/993,107 patent/US8865705B2/en active Active
-
2013
- 2013-04-09 IL IL225640A patent/IL225640A/en active IP Right Grant
- 2013-06-13 CL CL2013001713A patent/CL2013001713A1/es unknown
- 2013-06-14 ZA ZA2013/04424A patent/ZA201304424B/en unknown
-
2016
- 2016-06-22 CY CY20161100561T patent/CY1117751T1/el unknown
-
2018
- 2018-05-31 HK HK18107115.5A patent/HK1247616A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018511647A5 (enExample) | ||
| MY138906A (en) | Phenyl derivatives as ppar agonists | |
| JP2019524883A5 (enExample) | ||
| JP2014504622A5 (enExample) | ||
| JP2017510610A5 (enExample) | ||
| CA2517020A1 (en) | Dihydropteridinones, method for the production and use thereof in the form of drugs | |
| JP2017524025A5 (enExample) | ||
| JP2013500314A5 (enExample) | ||
| MD4490B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| JP2019517487A5 (enExample) | ||
| JP2008505157A5 (enExample) | ||
| JP2017533930A5 (enExample) | ||
| JP2024521979A5 (enExample) | ||
| NO20061406L (no) | Organiske forbindelser | |
| JP2019518050A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| CR20200584A (es) | Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
| CN108024938A (zh) | 改善的内酰胺溶解度 | |
| JP2016531126A5 (enExample) | ||
| JP2009538910A5 (enExample) | ||
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| MX393982B (es) | Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2). | |
| JP2021524482A5 (enExample) | ||
| RU2017112051A (ru) | Способ получения сложных эфиров астаксантина |